Introduction
============

Psoriasis is a chronic, immune mediated inflammatory skin disease,[@ref1] consisting of red, scaly plaques occurring most commonly on the elbows, knees, scalp, and lower back, but any skin surface can be involved. The condition greatly affects people's quality of life to the extent that it could be life ruining and stigmatising.[@ref2] Psoriasis is now considered a systemic disease; it is associated with psychological, metabolic, arthritic, and cardiovascular comorbidities. Lifespan is reduced as a consequence.[@ref3] In addition to the psychological and social burden related to psoriasis, the cost to patients and healthcare systems is high.[@ref4] Psoriasis can occur at any age, although most patients present with the condition before 35 years old.[@ref5] In 2014 the World Health Organization recognised psoriasis as a serious non-communicable disease[@ref6] and the accompanying WHO report (2016)[@ref6] emphasised the need to better understand the global burden of the disease. To address this need, the Global Psoriasis Atlas ([www.globalpsoriasisatlas.org](http://www.globalpsoriasisatlas.org)) was established to conduct further research into the global prevalence and incidence of psoriasis, thereby helping to ensure better access to care for people with the disease.

Studies that report information on the incidence of psoriasis are limited. Current estimates come from Europe and North America, and mainly report on the incidence of psoriasis in adults or in the overall population. Additionally, several studies have reported on the prevalence of psoriasis. Earlier study specific estimates of the prevalence of psoriasis in adults range between 0.27% (95% confidence interval 0.17 to 0.36)[@ref7] and 11.4%,[@ref8] with age, sex, geography, ethnicity, genetic and environmental factors contributing to the variation in the prevalence of the disease.[@ref9] Higher prevalence rates have been reported at higher latitudes and in white people compared with other ethnic groups.[@ref10]

The Global Burden of Disease group has generated estimates on the prevalence of psoriasis for 21 regions of the world,[@ref11] and more recently for the global population.[@ref12] These estimates relate to wider regions,[@ref11] [@ref12] but not to individual countries. Over the past decade there has been an increase in research examining the epidemiology of psoriasis, particularly in countries where estimates were lacking. Recent studies have often been derived from better data quality resources, many of them extracting information from large, routinely collected and electronic health databases, which are more nationally representative than previous studies.

Given the existing gaps in knowledge about the epidemiology of psoriasis, the aim of the study was to perform a systematic review and meta-analysis examining the incidence and prevalence of the disease. Additionally, the study aimed to generate global, regional, and country specific estimates of the prevalence of psoriasis.

Methods
=======

The systematic review and statistical model follow the PRISMA (preferred reporting items for systematic reviews and meta-analyses) and GATHER (guidelines for accurate and transparent health estimates reporting) guidelines (supplementary material 4, eTables 12 and 13, respectively).

Study design
------------

We conducted a systematic review of the incidence and prevalence of psoriasis that involved several steps. These steps included data identification and extraction; a descriptive summary of incidence data; and a statistical analysis to generate estimates of the global, regional, and country specific prevalence of psoriasis by using the information extracted from the included studies examining the prevalence of the disease.

Data identification and extraction
----------------------------------

### Search strategy

We systematically searched 11 electronic and regional databases (Medline, Embase, Web of Science, SciELO, Korean Journal Databases, Russian Science Citation Index, WPRIM, SaudiMedLit, Informit, IndMed, and HERDIN) from their respective inception dates to October 2019. The main search terms were "psoriasis" ("psoriatic skin," "pustulosis"), "incidence" ("incident studies" or "cohort studies," or "longitudinal studies"), and "prevalence" ("prevalent studies" or "cross-sectional studies"). Supplementary material 1 gives full details about the search strategy. We also screened the references of all included studies and published review articles to identify any additional eligible studies.

### Inclusion and exclusion criteria

We included studies if they reported on the prevalence or incidence of psoriasis in the general population. No language restrictions were applied. We also included studies that estimated the prevalence or incidence of other skin or autoimmune diseases, but provided data on psoriasis. Studies that used dermatology clinic case series, or specific subgroups of the population, or only focused on psoriatic arthritis were excluded.

### Data extraction

In the first stage, two authors (RP and IYKI) independently screened the titles and abstracts identified from searching the databases for eligibility. Eligible papers were critically appraised and those meeting the inclusion criteria were selected for data extraction. We critically appraised all included studies for risk of bias by using the appraisal tool for cross-sectional studies (AXIS).[@ref13] This quality assessment tool comprises 20 items that cover several domains: identification of research aim, appropriateness of study design, use of valid measures and statistical analyses, and consideration of bias. Supplementary material 1 (text 2.5) and supplementary material 3 (eTable 14) give full details about the AXIS tool, the items included, and the risk of bias assessment. Studies were classified as having high, medium, or low risk of bias, or were rated as unclear according to the quality of the methods used and results reported in the study. The two authors independently made these judgments, and reached consensus on the final rating if needed.

Analysis of incidence data
--------------------------

Because a limited number of studies reported on the incidence of psoriasis, these were summarised descriptively. We report incidence rates per 100 000 person years (95% confidence intervals). Results were analysed by country and age category (children, adults, or all ages), and if possible, we explored variation in the incidence of psoriasis within each country and age category.

Statistical analysis of prevalence data
---------------------------------------

After data extraction, we developed a filtering process for inclusion of studies in the statistical model because some studies used the same data resource. To prevent duplication, we included studies with the most recent or complete data on the variable of interest, or the most robust in terms of the methods used (supplementary material 1, eTable 2).

We fitted a bayesian hierarchical linear mixed model to estimate the global, regional, and country specific prevalence of psoriasis. This type of statistical model is considered the gold standard when data are sparse and heterogeneous.[@ref14] In the bayesian hierarchical model, estimates of the prevalence of psoriasis were informed by study data from the same country, if available, and by study data from other countries. We briefly describe the model below; supplementary material 2 (text 4) provides a full description.

The outcome was the log transformed prevalence of psoriasis, which allowed us to use a linear model and ensure predictions within the 0-100% range when back transformed. We mapped countries according to the Global Burden of Disease classification: 189 countries were nested in 21 regions, and regions were nested in seven super regions ([table 1](#tbl1){ref-type="table"}), the hierarchy of which mainly follows geography and income. High levels of heterogeneity in the global prevalence of psoriasis were expected for several reasons: varying age strata, or whether the prevalence was estimated in children, adults, or the overall population; type of diagnostic method, or whether the diagnosis was made by a physician, a dermatologist, or was self-reported; and type of estimate, or whether the estimate was calculated as point, period, or lifetime prevalence.[@ref8] Therefore, the hierarchical model had four levels (global, super regions, regions, and countries), four random intercepts for these, and three fixed covariates: age strata, type of diagnostic method (physician, dermatologist, or self-reported diagnosis), and type of prevalence measure (point, period, or lifetime prevalence). Age strata included children, adults, or the overall population (children and adults combined).

###### 

Countries and territories in analysis regions. The table gives the full details of the geographical groups and hierarchy used in the statistical model. The classification is the same as the one used by the Global Burden of Disease and by the United Nations.[@ref15] The hierarchy mainly follows geography and income

  Region                                                 Countries
  ------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Central Europe, eastern Europe, and central Asia**   
  Asia, central                                          Armenia, Azerbaijan, Georgia, Kazakhstan, Kyrgyzstan, Mongolia, Tajikistan, Turkmenistan, Uzbekistan
  Europe, central                                        Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, Montenegro, Poland, Romania, Serbia, Slovakia, Slovenia, TFYR Macedonia
  Europe, eastern                                        Belarus, Estonia, Latvia, Lithuania, Moldova, Russia, Ukraine
  **High income**                                        
  Asia Pacific, high income                              Brunei Darussalam, Japan, Republic of Korea, Singapore
  Australasia                                            Australia, New Zealand
  Europe, western                                        Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Israel, Italy, Luxembourg, Malta, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, United Kingdom
  Latin America, southern                                Argentina, Chile, Uruguay
  North America, high income                             Canada, United States of America
  **Latin America and Caribbean**                        
  Caribbean                                              Antigua and Barbuda, Bahamas, Barbados, Belize, Cuba, Dominican Republic, Grenada, Guyana, Haiti, Jamaica, Puerto Rico, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago, Virgin Island (US)
  Latin America, Andean                                  Bolivia, Ecuador, Peru
  Latin America, central                                 Colombia, Costa Rica, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Venezuela (Bolivarian Republic of)
  Latin America, tropical                                Brazil, Paraguay
  **North Africa and Middle East**                       
  North Africa and the Middle East                       Afghanistan, Algeria, Bahrain, Egypt, Iran (Islamic Republic of), Iraq, Jordan, Kuwait, Lebanon, Libyan Arab Jamahiriya, Morocco, Occupied Palestinian Territory, Oman, Qatar, Saudi Arabia, Sudan, Syrian Arab Republic, Sudan, Tunisia, Turkey, United Arab Emirates, Yemen
  **South Asia**                                         
  Asia, south                                            Bangladesh, Bhutan, India, Nepal, Pakistan
  **South East Asia, east Asia, and Oceania**            
  Asia, east                                             China, Dem. People's Republic of Korea, Taiwan
  Asia, South East                                       Cambodia, Indonesia, Lao People's Democratic Republic, Malaysia, Maldives, Mauritius, Myanmar, Philippines, Seychelles, Sri Lanka, Thailand, Timor-Leste, Vietnam
  Oceania                                                Fiji, Guam, Kiribati, Marshall Islands, Micronesia (Fed. States of), Papua New Guinea, Samoa, Solomon Islands, Tonga, Vanuatu
  **Sub-Saharan Africa**                                 
  Sub-Saharan Africa, central                            Angola, Central African Republic, Congo, Democratic Republic of the Congo, Equatorial Guinea, Gabon
  Sub-Saharan Africa, eastern                            Burundi, Comoros, Djibouti, Eritrea, Ethiopia, Kenya, Madagascar, Malawi, Mozambique, Rwanda, Somalia, South Sudan, Uganda, United Republic of Tanzania, Zambia
  Sub-Saharan Africa, southern                           Botswana, Lesotho, Namibia, South Africa, Swaziland, Zimbabwe
  Sub-Saharan Africa, western                            Benin, Burkina Faso, Côte d'Ivoire, Cameroon, Cape Verde, Chad, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, São Tomé and Príncipe, Senegal, Sierra Leone, Togo

We used geographical clustering in the model to inform and generate estimates for countries with missing information. In particular, for countries with no data available, the model estimates were based on borrowed evidence from higher levels. For example, the region estimate value was used for the country estimate when no country specific data were available; the super region estimate value was used for countries when no data were available within a region. It is also noteworthy that the region and super region estimates are always obtained from studies identified at the country level; therefore there are no regional or super regional level studies. Supplementary material 2 (eTables 6-11) reports information on countries with observed or missing data.

The statistical model was fitted using bayesian inference, sampling from the posterior distribution over the parameters by using the Hamiltonian Markov chain Monte Carlo method. We used four chains of 2000 iterations each to run the model. After fitting the model, posterior predictions were made for each country and age strata permutation. We provide prevalence estimates in the context of 95% uncertainty intervals. To obtain the number of people affected by psoriasis by country, each country specific prevalence estimate was multiplied by the size of its population; we used the United Nations population structure for the year 2017.[@ref15] We assessed the fit of each model by evaluating the measures relative to the effective sample size and autocorrelation, and the trace plots (supplementary material 2, eFig 2). All analyses were performed in R (version 3.6.1) by using the RStanArm package, which relies on Stan.

Patient and public involvement
------------------------------

The International Federation of Psoriasis Associations (IFPA) are a collaborating organisation on the Global Psoriasis Atlas. Members of IFPA include people with psoriasis and our work plans and findings were presented during Global Psoriasis Atlas Steering Group meetings at which IFPA members asked questions about the study design and findings.

Results
=======

We identified 41 164 records by searching the databases. Of the 308 papers that were critically appraised and assessed for eligibility, 168 reported on the incidence or prevalence of psoriasis in the general population (supplementary material 1, eFig 1). Specifically, nine studies focused on the incidence of psoriasis (eTable 1), 145 reported on the prevalence of psoriasis (eTable 2), and 14 studies reported on both incidence and prevalence (eTable 1).

Incidence of psoriasis
----------------------

The 23 studies that reported on the incidence of psoriasis in the general population were conducted mainly in western and eastern Europe (16 studies), and North America (six studies). Twelve studies reported on the incidence of psoriasis in all ages, with the incidence of the disease varying from 31.4 per 100 000 person years in eastern Europe (Russia)[@ref16] to 521.1 per 100 000 person years in western Europe (Germany).[@ref17] Springate and colleagues[@ref3] reported a slight decline in the incidence of psoriasis in all ages in the United Kingdom (from 159.0 to 129.0 per 100 000 person years between 1999 and 2013). Kubanova and colleagues[@ref18] also reported a slight decline in the incidence in Russia (from 69.8 to 65.0 per 100 000 person years between 2010 and 2016). However, the incidence of psoriasis in Denmark has been inconsistent, with a decrease from 140.1 to 104.0 per 100 000 person years between 2003 and 2005, followed by an increase to 181.0 in 2010, which then decreased to 151.2 in 2012 ([table 2](#tbl2){ref-type="table"}).[@ref19]

###### 

List of studies providing incidence rates in children, adults, and all ages

  Study, country, study period       Diagnostic method            Age of population           No with psoriasis           Incidence rate per 100 000 person years (95% CI)                              
  ---------------------------------- ---------------------------- --------------------------- --------------------------- -------------------------------------------------- -------------------------- --------------------------
  **Children**                                                                                                                                                                                          
  Cantarutti et al (2015), Italy                                                                                                                                                                        
   2006-12                           Family paediatrician         ≤14                         ---                         ---                                                ---                        ---
   2006                              61.0 (50.0 to 80.0)\*        ---                         ---                                                                                                       
   2007                              45.0 (30.0 to 60.0)\*        ---                         ---                                                                                                       
   2008                              54.0 (40.0 to 70.0)\*        ---                         ---                                                                                                       
   2009                              53.0 (40.0 to 70.0)\*        ---                         ---                                                                                                       
   2010                              53.0 (40.0 to 70.0)\*        ---                         ---                                                                                                       
   2011                              40.0 (30.0 to 50.0)\*        ---                         ---                                                                                                       
   2012                              57.0 (40.0 to 80.0)\*        ---                         ---                                                                                                       
  Tollefson et al (2010), US                                                                                                                                                                            
   1970-99                           Dermatologist or physician   \<18                        357                         40.8 (36.6 to 45.1)\*†                             43.9 (37.6 to 50.2)\*†     37.9 (32.2 to 43.6)\*†
   1970-74                           29.6 (20.9 to 38.3)\*†       ---                         ---                                                                                                       
   1975-79                           35.7 (25.9 to 45.5)\*†       ---                         ---                                                                                                       
   1980-84                           31.4 (22.0 to 40.8)\*†       ---                         ---                                                                                                       
   1985-89                           42.7 (31.8 to 53.7)\*†       ---                         ---                                                                                                       
   1990-94                           40.0 (29.7 to 50.3)\*†       ---                         ---                                                                                                       
   1995-99                           62.7 (50.4 to 65.0)\*†       ---                         ---                                                                                                       
  **Adults**                                                                                                                                                                                            
  Eder et al (2017), Canada                                                                                                                                                                             
   2000-15                           Physician                    ≥20                         ---                         ---                                                ---                        ---
   2000                              114.0 (112.0 to 116.0)\*†    ---                         ---                                                                                                       
   2001                              111.0 (109.0 to 113.0)\*†    ---                         ---                                                                                                       
   2002                              103.0 (101.0 to 105.0)\*†    ---                         ---                                                                                                       
   2003                              101.0 (99.0 to 103.0)\*†     ---                         ---                                                                                                       
   2004                              101.0 (99.0 to 103.0)\*†     ---                         ---                                                                                                       
   2005                              97.0 (95.0 to 99.0)\*†       ---                         ---                                                                                                       
   2006                              97.0 (95.0 to 99.0)\*†       ---                         ---                                                                                                       
   2007                              96.0 (94.0 to 98.0)\*†       ---                         ---                                                                                                       
   2008                              96.0 (94.0 to 98.0)\*†       ---                         ---                                                                                                       
   2009                              95.0 (93.0 to 97.0)\*†       ---                         ---                                                                                                       
   2010                              95.0 (93.0 to 97.0)\*†       ---                         ---                                                                                                       
   2011                              98.0 (96.0 to 100.0)\*†      ---                         ---                                                                                                       
   2012                              100.0 (98.0 to 102.0)\*†     ---                         ---                                                                                                       
   2013                              105.0 (103.0 to 107.0)\*†    ---                         ---                                                                                                       
   2014                              102.0 (100.0 to 104.0)\*†    ---                         ---                                                                                                       
   2015                              105.0 (103.0 to 107.0)\*†    ---                         ---                                                                                                       
  Eder et al (2019), Canada                                                                                                                                                                             
   2000-15                           Physician                    ≥20                         ---                         ---                                                ---                        ---
   2000                              9873                         111.1 (108.9 to 113.4)\*†   ---                         ---                                                                           
   2001                              9849                         108.6 (106.5 to 110.8)\*†   ---                         ---                                                                           
   2002                              9203                         99.7 (97.6 to 101.8)\*†     ---                         ---                                                                           
   2003                              9111                         97.3 (95.3 to 99.3)\*†      ---                         ---                                                                           
   2004                              9060                         95.3 (93.3 to 97.3)\*†      ---                         ---                                                                           
   2005                              8645                         89.8 (87.9 to 91.8)\*†      ---                         ---                                                                           
   2006                              8979                         92.7 (90.7 to 94.7)\*†      ---                         ---                                                                           
   2007                              8601                         87.6 (85.7 to 89.6)\*†      ---                         ---                                                                           
   2008                              8585                         85.9 (84.0 to 87.8)\*†      ---                         ---                                                                           
   2009                              8610                         85.2 (83.4 to 87.1)\*†      ---                         ---                                                                           
   2010                              8399                         81.8 (80.0 to 83.7)\*†      ---                         ---                                                                           
   2011                              8868                         85.0 (83.2 to 86.9)\*†      ---                         ---                                                                           
   2012                              8883                         83.9 (82.1 to 85.7)\*†      ---                         ---                                                                           
   2013                              8789                         82.1 (80.3 to 83.9)\*†      ---                         ---                                                                           
   2014                              8212                         76.1 (74.4 to 77.9)\*†      ---                         ---                                                                           
   2015                              7541                         68.7 (67.1 to 70.3)\*†      ---                         ---                                                                           
  Vena et al (2010), Italy                                                                                                                                                                              
   2001-05                           Physician                    ≥18                         5792                        ---                                                ---                        ---
   2001                              321.0\*                      291.0\*                     357.0\*                                                                                                   
   2005                              230.0\*                      207.0\*                     254.0\*                                                                                                   
  Pezzolo et al (2019), Italy                                                                                                                                                                           
   2003-04                           Self-reported diagnosis      ≥25                         ---                         302 (232 to 392)\*                                 380 (270 to 535)\*         296 (197 to 443)\*
  Wei et al (2018), Taiwan                                                                                                                                                                              
   2001                              ---                          ≥16                         333                         42.0 (37.5 to 46.5)\*†                             ---                        ---
   2002                              320                          40.1 (35.7 to 44.5)\*†      ---                         ---                                                                           
   2003                              329                          41.7 (37.2 to 46.3)\*†      ---                         ---                                                                           
   2004                              370                          46.9 (42.1 to 51.8)\*†      ---                         ---                                                                           
   2005                              272                          33.8 (29.7 to 37.8)\*†      ---                         ---                                                                           
   2006                              325                          39.7 (35.3 to 44.1)\*†      ---                         ---                                                                           
   2007                              295                          35.7 (31.5 to 39.8)\*†      ---                         ---                                                                           
   2008                              291                          34.1 (30.1 to 38.2)\*†      ---                         ---                                                                           
   2009                              322                          37.8 (33.5 to 42.0)\*†      ---                         ---                                                                           
   2010                              316                          36.7 (32.5 to 40.9)\*†      ---                         ---                                                                           
   2011                              338                          40.3 (35.8 to 44.8)\*†      ---                         ---                                                                           
   2012                              327                          37.2 (33.0 to 41.5)\*†      ---                         ---                                                                           
   2013                              273                          30.3 (26.6 to 34.1)\*†      ---                         ---                                                                           
  Khalid et al (2013), UK                                                                                                                                                                               
   2007-09                           Physician                    ≥18                         10 832                      280.0 (280.0 to 290.0)\*†                          ---                        ---
  Tillett et al (2017), UK                                                                                                                                                                              
   1998-2014                         Physician                    ≥18                         88 858                      183.0 (182.0 to 184.0)\*                           186.0 (184.0 to 188.0)\*   179.0 (178.0 to 181.0)\*
  Shbeeb et al (1995), US                                                                                                                                                                               
   1982-91                           ---                          ---                         ---                         78.0 (70.0 to 86.0)\*†                             ---                        ---
  Icen et al (2009), US                                                                                                                                                                                 
   1970-2000                         Dermatologist or physician   ≥18                         1633                        78.9 (75.0 to 82.9)\*†‡                            73.2 (68.0 to 78.4)\*†‡    85.5 (79.5 to 91.6)\*†‡
   1970-74                           50.8 (41.9 to 59.6)\*†‡      ---                         ---                                                                                                       
   1975-79                           53.2 (44.8 to 61.6)\*†‡      ---                         ---                                                                                                       
   1980-84                           80.9 (70.8 to 91.1)\*†‡      ---                         ---                                                                                                       
   1985-89                           78.9 (69.5 to 88.4)\*†‡      ---                         ---                                                                                                       
   1990-94                           88.7 (79.1 to 98.3)\*†‡      ---                         ---                                                                                                       
   1995-99                           100.5 (90.8 to 110.2)\*†‡    ---                         ---                                                                                                       
  **All ages**                                                                                                                                                                                          
  Egeberg et al (2017), Denmark                                                                                                                                                                         
   2003-12                           Physician                    0-70+                       ---                         ---                                                ---                        ---
   2003                              140.1 (137.1 to 143.2)\*     146.8\*                     133.4\*                                                                                                   
   2004                              122.2 (119.4 to 125.1)\*     130.7\*                     113.6\*                                                                                                   
   2005                              104.0 (101.4 to 106.7)\*     107.5\*                     100.5\*                                                                                                   
   2006                              105.5 (102.9 to 108.2)\*     110.4\*                     100.4\*                                                                                                   
   2007                              111.5 (108.7 to 114.2)\*     110.8\*                     112.2\*                                                                                                   
   2008                              128.6 (125.7 to 131.6)\*     128.8\*                     128.4\*                                                                                                   
   2009                              174.8 (171.4 to 178.3)\*     192.6\*                     156.8\*                                                                                                   
   2010                              181.0 (177.5 to 184.5)\*     199.5\*                     162.3\*                                                                                                   
   2011                              171.3 (167.9 to 174.7)\*     187.9\*                     154.5\*                                                                                                   
   2012                              151.2 (148.0 to 154.5)\*     165.9\*                     136.4\*                                                                                                   
  Jacob et al (2016), Germany                                                                                                                                                                           
   2007-10                           Physician                    ---                         14 686                      521.1\*                                            ---                        ---
  Sewerin et al (2019), Germany                                                                                                                                                                         
   2009                              ---                          ---                         ---                         ---                                                46.3 to 58.2\*             35.4 to 50.3\*
   2010                              35.3 to 45.6\*               26.4 to 39.4\*                                                                                                                        
   2011                              21.7 to 30.5\*               17.3 to 29.3\*                                                                                                                        
   2012                              19.1 to 26.4\*               17.1 to 26.3\*                                                                                                                        
  Shalom et al (2018), Israel                                                                                                                                                                           
   2016                              ---                          ---                         ---                         246 (241 to 251)\*†                                ---                        ---
   2017                              243 (239 to 248)\*†          ---                         ---                                                                                                       
  Schonmann et al (2019), Israel                                                                                                                                                                        
   2011                              Dermatologist                0-85+                       9770                        282 (276 to 288)\*†                                268 (261 to 276)\*†        296 (287 to 305)\*†
   2012                              9796                         278 (272 to 284)\*†         273 (265 to 281)\*†         283 (275 to 292)\*†                                                           
   2013                              10 430                       291 (285 to 297)\*†         278 (270 to 286)\*†         304 (295 to 312)\*†                                                           
   2014                              10 072                       276 (271 to 282)\*†         263 (256 to 271)\*†         290 (281 to 298)\*†                                                           
   2015                              10 033                       273 (267 to 279)\*†         257 (250 to 265)\*†         289 (280 to 297)\*†                                                           
   2016                              10 505                       281 (276 to 287)\*†         269 (261 to 276)\*†         294 (286 to 302)\*†                                                           
   2017                              10 489                       276 (270 to 281)\*†         263 (256 to 271)\*†         288 (280 to 296)\*†                                                           
  Znamenskaya et al (2012), Russia                                                                                                                                                                      
   2009                              Physician                    0-18+                       99 988                      70.5\*                                             ---                        ---
   2010                              99 348                       69.8\*                      ---                         ---                                                                           
   2011                              99 436                       69.6\*                      ---                         ---                                                                           
  Kubanova et al (2017), Russia                                                                                                                                                                         
   2010                              Physician                    0-18+                       ---                         69.8\*                                             ---                        ---
   2011                              69.6\*                       ---                         ---                                                                                                       
   2012                              68.4\*                       ---                         ---                                                                                                       
   2013                              65.9\*                       ---                         ---                                                                                                       
   2014                              64.7\*                       ---                         ---                                                                                                       
   2015                              62.8\*                       ---                         ---                                                                                                       
   2016                              65.0\*                       ---                         ---                                                                                                       
  Odinets et al (2017), Russia                                                                                                                                                                          
   2010                              Physician                    0-18+                       1180                        42.5\*                                             ---                        ---
   2011                              1136                         40.8\*                      ---                         ---                                                                           
   2012                              1257                         45.1\*                      ---                         ---                                                                           
   2013                              875                          31.4\*                      ---                         ---                                                                           
   2014                              945                          33.8\*                      ---                         ---                                                                           
   2015                              941                          33.6\*                      ---                         ---                                                                           
   2016                              1094                         39.0\*                      ---                         ---                                                                           
  Donker et al (1998), Netherlands                                                                                                                                                                      
   1987-88                           Physician                    0-65+                       106                         130.0 (120.0 to 140.0)\*†                          ---                        ---
  Donker et al (1998), Netherlands                                                                                                                                                                      
   1995                              Physician                    0-65+                       24                          120.0 (70.0 to 190.0)\*†                           ---                        ---
  Huerta et al (2007), UK                                                                                                                                                                               
   1996-97                           Physician                    0-80+                       3994                        140.0\*                                            ---                        ---
  Springate et al (2017), UK                                                                                                                                                                            
   1999-2013                         Physician                    0-100                       ---                         ---                                                ---                        ---
   1999                              4279                         159.0 (155.0 to 164.0)\*†   161.0 (155.0 to 168.0)\*†   158.0 (151.0 to 165.0)\*†                                                     
   2000                              5398                         163.0 (158.0 to 167.0)\*†   162.0 (156.0 to 169.0)\*†   163.0 (157.0 to 170.0)\*†                                                     
   2001                              6286                         164.0 (160.0 to 168.0)\*†   163.0 (157.0 to 168.0)\*†   166.0 (160.0 to 172.0)\*†                                                     
   2002                              7259                         170.0 (166.0 to 174.0)\*†   174.0 (169.0 to 180.0)\*†   166.0 (161.0 to 172.0)\*†                                                     
   2003                              7977                         172.0 (168.0 to 176.0)\*†   178.0 (173.0 to 183.0)\*†   166.0 (161.0 to 172.0)\*†                                                     
   2004                              8209                         166.0 (163.0 to 170.0)\*†   170.0 (165.0 to 175.0)\*†   163.0 (158.0 to 168.0)\*†                                                     
   2005                              8522                         165.0 (162.0 to 169.0)\*†   173.0 (168.0 to 178.0)\*†   158.0 (153.0 to 163.0)\*†                                                     
   2006                              8499                         161.0 (158.0 to 165.0)\*†   169.0 (164.0 to 174.0)\*†   154.0 (149.0 to 159.0)\*†                                                     
   2007                              8807                         165.0 (162.0 to 168.0)\*†   170.0 (165.0 to 175.0)\*†   160.0 (155.0 to 165.0)\*†                                                     
   2008                              8964                         163.0 (160.0 to 167.0)\*†   165.0 (160.0 to 170.0)\*†   162.0 (157.0 to 167.0)\*†                                                     
   2009                              8518                         155.0 (152.0 to 158.0)\*†   159.0 (154.0 to 163.0)\*†   152.0 (147.0 to 156.0)\*†                                                     
   2010                              7715                         143.0 (140.0 to 146.0)\*†   145.0 (141.0 to 150.0)\*†   140.0 (136.0 to 145.0)\*†                                                     
   2011                              7499                         140.0 (137.0 to 143.0)\*†   144.0 (140.0 to 149.0)\*†   135.0 (131.0 to 140.0)\*†                                                     
   2012                              6992                         131.0 (128.0 to 134.0)\*†   136.0 (132.0 to 141.0)\*†   126.0 (122.0 to 130.0)\*†                                                     
   2013                              6350                         129.0 (126.0 to 133.0)\*†   131.0 (127.0 to 136.0)\*†   127.0 (123.0 to 132.0)\*†                                                     
  Bell et al (1991), US                                                                                                                                                                                 
   1980-83                           Dermatologist or physician   0-70+                       132                         59.9 (49.5 to 70.3)\*†                             63.6 (48.9 to 78.3)\*†     58.4 (42.8 to 74.1)\*†

Values reported from the study.

Age or sex adjusted.

Rate adjusted with linear interpolation between census years.

Only two studies, from Italy and the United States, explored the incidence of psoriasis in children over a seven year and 30 year period, respectively ([table 2](#tbl2){ref-type="table"}).[@ref20] [@ref21] While Tollefson and colleagues[@ref21] reported a steady rise in the incidence of psoriasis in the US between 1970 and 2000, Cantarutti and colleagues[@ref20] found that the incidence of psoriasis in Italy was stable between 2006 and 2012 ([table 2](#tbl2){ref-type="table"}).

The incidence of psoriasis was higher in adults than in children, varying from 30.3 per 100 000 person years (95% confidence interval 26.6 to 34.1)[@ref22] in Taiwan to 321.0 per 100 000 person years in Italy.[@ref23] While the data show a steadily increasing trend in incidence of psoriasis in adults in the US between 1970 and 2000 ([table 2](#tbl2){ref-type="table"}),[@ref24] data from Canada, Italy, and Taiwan show a slightly decreasing trend in incidence over time.[@ref22] [@ref23] [@ref25]

Variation in the incidence of psoriasis by age and sex
------------------------------------------------------

The incidence of psoriasis in children increased with age from 13.5 per 100 000 person years (0-3 years old) to 53.1 per 100 000 person years (14-18 years old; [table 3](#tbl3){ref-type="table"}).[@ref21] Despite higher estimates of psoriasis incidence from the UK[@ref26] [@ref27] than the US,[@ref24] [@ref28] all of these studies showed a similar trend of increasing psoriasis incidence up to 39 years of age. The incidence then decreased at 40-49 years before increasing again with a second peak at around 50-59 years (UK[@ref27]) or 60-69 years (UK[@ref26] and US[@ref24] [@ref28]). The incidence of psoriasis decreased towards the end of life.

###### 

List of studies providing incidence rates -by sex and age groups

  Study, country, and study period   Diagnostic method            Age of population          No with psoriasis          Incidence rate per 100 000 person years (95% CI)                              
  ---------------------------------- ---------------------------- -------------------------- -------------------------- -------------------------------------------------- -------------------------- --------------------------
  **Children**                                                                                                                                                                                        
  Tollefson et al (2010), US                                                                                                                                                                          
   1970-99                           Dermatologist or physician   \<18                       357                        40.8 (36.6 to 45.1)\*†                             43.9 (37.6 to 50.2)\*†     37.9 (32.2 to 43.6)\*†
  0-3                                27                           13.5\*                     13.2\*                     13.7\*                                                                        
  4-7                                84                           42.2\*                     40.2\*                     44.1\*                                                                        
  8-10                               69                           44.0\*                     55.7\*                     33.2\*                                                                        
  11-13                              75                           52.2\*                     49.6\*                     54.6\*                                                                        
  14-17                              102                          53.1\*                     61.9\*                     44.7\*                                                                        
  **Adults**                                                                                                                                                                                          
  Pezzolo et al (2019), Italy                                                                                                                                                                         
   2003-04                           Self-reported diagnosis      ≥25                        ---                        302 (232 to 392)\*                                 380 (270 to 535)\*         296 (197 to 443)\*
  \<35                               ---                          186 (95 to 365)\*          236 (101 to 554)\*         137 (45 to 412)\*                                                             
  35-44                              ---                          342 (193 to 605)\*         251 (98 to 642)\*          433 (211 to 889)\*                                                            
  45-54                              ---                          219 (110 to 435)\*         339 (156 to 739)\*         96 (22 to 419)\*                                                              
  55-64                              ---                          385 (223 to 665)\*         492 (252 to 961)\*         269 (105 to 690)\*                                                            
  65-74                              ---                          420 (253 to 697)\*         395 (199 to 782)\*         456 (214 to 969)\*                                                            
  ≥74                                ---                          ---                        ---                        ---                                                                           
  Khalid et al (2013), UK                                                                                                                                                                             
   2007-09                           Physician                    ≥18                        10 832                     280.0 (280.0 to 290.0)\*†                          ---                        ---
  18-29                              ---                          350.0 (320.0 to 380.0)\*   250.0 (230.0 to 280.0)\*                                                                                 
  30-39                              ---                          320.0 (280.0 to 350.0)\*   290.0 (260.0 to 320.0)\*                                                                                 
  40-49                              ---                          220.0 (200.0 to 240.0)\*   220.0 (200.0 to 250.0)\*                                                                                 
  50-59                              ---                          310.0 (280.0 to 340.0)\*   320.0 (300.0 to 360.0)\*                                                                                 
  60-69                              ---                          310.0 (280.0 to 350.0)\*   370.0 (330.0 to 400.0)\*                                                                                 
  70-79                              ---                          290.0 (250.0 to 320.0)\*   290.0 (250.0 to 330.0)\*                                                                                 
  ≥80                                ---                          160.0 (130.0 to 190.0)\*   180.0 (140.0 to 230.0)\*                                                                                 
  Tillett et al (2017), UK                                                                                                                                                                            
   1998-2014                         Physician                    ≥18                        88 858                     183.0 (182.0 to 184.0)\*                           186.0 (184.0 to 188.0)\*   179.0 (178.0 to 181.0)\*
  18-29                              14 292                       174.0 (171.0 to 177.0)\*   193.0 (188.0 to 197.0)\*   157.0 (154.0 to 161.0)\*                                                      
  30-39                              15 169                       176.0 (173.0 to 179.0)\*   182.0 (178.0 to 186.0)\*   170.0 (166.0 to 173.0)\*                                                      
  40-49                              15 423                       164.0 (162.0 to 167.0)\*   158.0 (155.0 to 162.0)\*   170.0 (166.0 to 174.0)\*                                                      
  50-59                              16 218                       195.0 (192.0 to 198.0)\*   200.0 (196.0 to 204.0)\*   190.0 (186.0 to 194.0)\*                                                      
  60-69                              14 536                       216.0 (213.0 to 220.0)\*   217.0 (212.0 to 222.0)\*   216.0 (211.0 to 221.0)\*                                                      
  70-79                              9364                         196.0 (192.0 to 204.0)\*   196.0 (191.0 to 201.0)\*   197.0 (191.0 to 203.0)\*                                                      
  80-89                              3856                         149.0 (145.0 to 154.0)\*   145.0 (139.0 to 151.0)\*   157.0 (150.0 to 165.0)\*                                                      
  Icen et al (2009), US                                                                                                                                                                               
   1970-2000                         Dermatologist or physician   ≥18                        1633                       78.9 (75.0 to 82.9)\*†‡                            73.2 (68.0 to 78.4)\*†‡    85.5 (79.5 to 91.6)\*†‡
  18-29                              444                          77.4\*                     75.6\*                     79.4\*                                                                        
  30-39                              391                          81.1\*                     69.2\*                     93.3\*                                                                        
  40-49                              260                          71.3\*                     69.0\*                     73.6\*                                                                        
  50-59                              230                          88.0\*                     90.7\*                     85.2\*                                                                        
  60-69                              174                          94.2\*                     76.2\*                     115.3\*                                                                       
  70-79                              94                           73.8\*                     71.2\*                     77.9\*                                                                        
  ≥80                                40                           51.4\*                     39.8\*                     80.0\*                                                                        
  **All ages**                                                                                                                                                                                        
  Schonmann et al (2019), Israel                                                                                                                                                                      
   2015                              Dermatologist                \<1                        ---                        23.0\*                                             ---                        ---
  1-4                                ---                          58.0\*                     ---                        ---                                                                           
  5-14                               ---                          117.0\*                    ---                        ---                                                                           
  15-24                              ---                          186.0\*                    ---                        ---                                                                           
  25-34                              ---                          315.0\*                    ---                        ---                                                                           
  35-44                              ---                          299.0\*                    ---                        ---                                                                           
  45-54                              ---                          302.0\*                    ---                        ---                                                                           
  55-64                              ---                          347.0\*                    ---                        ---                                                                           
  65-74                              ---                          350.0\*                    ---                        ---                                                                           
  75-84                              ---                          288.0\*                    ---                        ---                                                                           
  ≥85                                ---                          173.0\*                    ---                        ---                                                                           
  Znamenskaya et al (2012), Russia                                                                                                                                                                    
   2009                              Physician                    0-18+                      99 988                     70.5\*                                             ---                        ---
  0-14                               6069                         28.8\*                     ---                        ---                                                                           
  15-17                              5864                         118.2\*                    ---                        ---                                                                           
  ≥18                                88 055                       76.0\*                     ---                        ---                                                                           
   2010                              0-18+                        99 348                     69.8\*                     ---                                                ---                        
  0-14                               6045                         28.2\*                     ---                        ---                                                                           
  15-17                              5873                         128.2\*                    ---                        ---                                                                           
  ≥18                                87 430                       75.4\*                     ---                        ---                                                                           
   2011                              0-18+                        99 436                     69.6\*                     ---                                                ---                        
  0-14                               6104                         28.0\*                     ---                        ---                                                                           
  15-17                              5681                         126.7\*                    ---                        ---                                                                           
  ≥18                                87 651                       75.2\*                     ---                        ---                                                                           
  Kubanova et al (2017), Russia                                                                                                                                                                       
   2010                              Physician                    0-18+                      ---                        69.8\*                                             ---                        ---
  0-14                               ---                          27.9\*                     ---                        ---                                                                           
  15-17                              ---                          127.2\*                    ---                        ---                                                                           
  ≥18                                ---                          75.4\*                     ---                        ---                                                                           
   2011                              0-18+                        ---                        69.6\*                     ---                                                ---                        
  0-14                               ---                          28.0\*                     ---                        ---                                                                           
  15-17                              ---                          126.7\*                    ---                        ---                                                                           
  ≥18                                ---                          75.2\*                     ---                        ---                                                                           
   2012                              0-18+                        ---                        68.4\*                     ---                                                ---                        
  0-14                               ---                          27.8\*                     ---                        ---                                                                           
  15-17                              ---                          118.8\*                    ---                        ---                                                                           
  ≥18                                ---                          74.2\*                     ---                        ---                                                                           
   2013                              0-18+                        ---                        65.9\*                     ---                                                ---                        
  0-14                               ---                          27.3\*                     ---                        ---                                                                           
  15-17                              ---                          115.6\*                    ---                        ---                                                                           
  ≥18                                ---                          71.7\*                     ---                        ---                                                                           
   2014                              0-18+                        ---                        64.7\*                     ---                                                ---                        
  0-14                               ---                          25.1\*                     ---                        ---                                                                           
  15-17                              ---                          108.4\*                    ---                        ---                                                                           
  ≥18                                ---                          72.4\*                     ---                        ---                                                                           
   2015                              0-18+                        ---                        62.8\*                     ---                                                ---                        
  0-14                               ---                          24.0\*                     ---                        ---                                                                           
  15-17                              ---                          99.3\*                     ---                        ---                                                                           
  ≥18                                ---                          69.6\*                     ---                        ---                                                                           
   2016                              0-18+                        ---                        65.0\*                     ---                                                ---                        
  0-14                               ---                          24.3\*                     ---                        ---                                                                           
  15-17                              ---                          95.6\*                     ---                        ---                                                                           
  ≥18                                ---                          72.6\*                     ---                        ---                                                                           
  Huerta et al (2007), UK                                                                                                                                                                             
   1996-97                           Physician                    0-80+                      3994                       140.0\*                                            ---                        ---
  0-19                               116.0\*                      121.0\*                    110.0\*                                                                                                  
  20-29                              134.0\*                      155.0\*                    111.0\*                                                                                                  
  30-39                              155.0\*                      131.0\*                    174.0\*                                                                                                  
  40-49                              116.0\*                      105.0\*                    128.0\*                                                                                                  
  50-59                              167.0\*                      172.0\*                    161.0\*                                                                                                  
  60-69                              164.0\*                      144.0\*                    186.0\*                                                                                                  
  70-79                              163.0\*                      118.0\*                    224.0\*                                                                                                  
  ≥80                                100.0\*                      82.0\*                     173.0\*                                                                                                  
  Bell et al (1991), US                                                                                                                                                                               
   1980-83                           Dermatologist or physician   0-70+                      132                        59.9 (49.5 to 70.3)\*†                             63.6 (48.9 to 78.3)\*†     58.4 (42.8 to 74.1)\*†
  \<20                               21                           30.9\*                     47.1\*                     14.8\*                                                                        
  20-29                              25                           49.1\*                     41.3\*                     59.5\*                                                                        
  30-39                              25                           71.7\*                     61.2\*                     82.9\*                                                                        
  40-49                              12                           51.4\*                     58.6\*                     43.8\*                                                                        
  50-59                              18                           94.6\*                     109.1\*                    78.3\*                                                                        
  60-69                              17                           112.6\*                    126.5\*                    93.8\*                                                                        
  ≥70                                14                           77.4\*                     54.9\*                     130.6\*                                                                       

Values reported from the study.

Age or sex adjusted.

We found a lack of agreement in the published studies about variations in incidence rates by sex. Although the overall incidence rate was higher in girls than in boys aged less than 18 years (43.9 and 37.9 per 100 000 person years, respectively), this pattern was not consistent across all age bands.[@ref21] Some studies reported higher incidence in women than in men,[@ref3] [@ref19] [@ref26] [@ref28] whereas other studies presented contrasting results.[@ref23] [@ref24] When we examined the incidence of psoriasis by sex and age bands, the two peaks for age at onset in women were more frequently around 18-29 and 50-59 years, whereas in men they occurred more frequently around 30-39 and 60-69 or 70-79 years.[@ref24] [@ref26] [@ref27] [@ref28]

Prevalence of psoriasis
-----------------------

The 159 studies that reported on the prevalence of psoriasis in the general population were identified from 12 regions of the world ([table 4](#tbl4){ref-type="table"}). Most studies (107; 67%) were conducted in high income countries; these also contributed the highest number of nationally representative studies. Because of overlapping data sources, we included 129 independent data points in the statistical analysis; these came from 35 out of 189 (19%) countries of the world ([fig 1](#f1){ref-type="fig"}). Most studies included in the statistical analyses were graded as low-medium risk of bias (76%; supplementary material 3, eTable 14). Supplementary material 2 (eTables 6-11) reports estimates of lifetime prevalence of psoriasis for the main analyses for each age stratum according to physician or dermatologist diagnosis, and self-reported lifetime prevalence; however, the number of people affected by psoriasis is reported for the adult population only.

###### 

Distribution of studies (n=159) reporting on the prevalence of psoriasis according to regions

  Region                             No of studies\*
  ---------------------------------- -----------------
  Western Europe                     97
  High income North America          20
  East Asia                          16
  North Africa and the Middle East   18
  Central Europe                     6
  Tropical Latin America             5
  High income Asia Pacific           4
  Australasia                        3
  Eastern Europe                     4
  South Asia                         3
  South East Asia                    1
  Eastern sub-Saharan Africa         1

The number of studies is higher than 159 because some studies reported data on many countries belonging to different regions.

![Distribution of number of studies included in statistical analysis by country. Countries with no observed data are white](parr052230.f1){#f1}

Regionally, the occurrence of the disease for the overall population varied from 0.11% (95% uncertainty interval 0.04% to 0.30%) in east Asia to 1.58% (0.50% to 5.73%) in Australasia, and 1.52% (0.87% to 2.74%) in western Europe ([fig 2](#f2){ref-type="fig"}). Country specific prevalence of psoriasis varied substantially. Considering the estimate for the overall population, Australia (1.88%, 0.59% to 6.10%), Norway (1.86%, 0.94% to 3.97%), Israel (1.81%, 0.83% to 4.44%), and Denmark (1.79%, 0.91% to 3.61%) had the highest estimates of the prevalence of psoriasis (supplementary material 2, eTable 8). The estimated prevalence of psoriasis in countries from east Asia was much lower, Taiwan being the country with the lowest prevalence worldwide (0.05%; 0.02% to 0.16%).

![Crude lifetime (physician or dermatologist diagnosed) prevalence of psoriasis for overall population according to world regions. Regions with observed data: Australasia, central Europe, east Asia, eastern Europe, eastern sub-Saharan Africa, high income Asia Pacific, high income North America, North Africa and the Middle East, south Asia, South East Asia, tropical Latin America, western Europe. Regions with extrapolated data: central Asia, high income southern Latin America, Caribbean, Andean Latin America, central Latin America, Oceania, central sub-Saharan Africa, southern sub-Saharan Africa, western sub-Saharan Africa](parr052230.f2){#f2}

Psoriasis occurred more frequently in adults than in children. The prevalence of psoriasis in children varied from 0.02% (95% uncertainty interval 0.01% to 0.04%) in east Asia to 0.22% (0.06% to 0.81%) in Australasia and 0.21% (0.11% to 0.41%) in western Europe ([fig 3](#f3){ref-type="fig"}). In adults, the disease varied from 0.14% (0.05% to 0.40%) in east Asia to 1.99% (0.64% to 6.60%) in Australasia. Other regions with an occurrence of the disease above 1% were western Europe (1.92%, 1.07% to 3.46%), central Europe (1.83%, 0.62% to 5.32%), high income North America (1.50%, 0.63% to 3.60%), and high income southern Latin America (1.10%, 0.36% to 2.96%; [fig 4](#f4){ref-type="fig"}).

![Crude lifetime (physician or dermatologist diagnosed) prevalence of psoriasis in children according to world regions. Regions with observed data: Australasia, central Europe, east Asia, eastern Europe, eastern sub-Saharan Africa, high income Asia Pacific, high income North America, North Africa and the Middle East, south Asia, South East Asia, tropical Latin America, western Europe. Regions with extrapolated data: central Asia, high income southern Latin America, Caribbean, Andean Latin America, central Latin America, Oceania, central sub-Saharan Africa, southern sub-Saharan Africa, western sub-Saharan Africa](parr052230.f3){#f3}

![Crude lifetime (physician or dermatologist diagnosed) prevalence of psoriasis in adults according to world regions. Regions with observed data: Australasia, central Europe, east Asia, eastern Europe, eastern sub-Saharan Africa, high income Asia Pacific, high income North America, North Africa and the Middle East, south Asia, South East Asia, tropical Latin America, western Europe. Regions with extrapolated data: central Asia, high income southern Latin America, Caribbean, Andean Latin America, central Latin America, Oceania, central sub-Saharan Africa, southern sub-Saharan Africa, western sub-Saharan Africa](parr052230.f4){#f4}

Given the strong association of psoriasis with age, the prevalence of psoriasis also varied across countries because of differences in regional and country specific age structures. Considering country specific estimates, the physician diagnosed lifetime prevalence of psoriasis in adults was highest in Australia (2.38%, 0.78% to 7.01%), Norway (2.36%, 1.10% to 5.04%), Israel (2.28%, 0.98% to 5.65%), Denmark (2.26%, 1.15% to 4.58%), Romania (2.24%, 0.76% to 6.73%), Germany (2.20%, 1.12% to 4.38%), Sweden (2.10%, 0.94% to 4.74%), Poland (2.06%, 0.61% to 6.58%), and Italy (2.00%, 1.00% to 4.14%; [fig 5](#f5){ref-type="fig"} and eTable 7, supplementary material 2). However, the countries with the highest number of adults affected were the US (3.4 million, 95% uncertainty interval 1.5 to 7.7 million), India (2.9 million, 0.8 to 10.0 million), China (2.3 million, 0.9 to 6.1 million), Germany (1.5 million, 0.8 to 2.9 million), Brazil (1.2 million, 0.3 to 4.8 million), France (1.0 million, 0.5 to 2.1 million), and the UK (1.0 million, 0.5 to 1.9). Globally, in 2017, an estimated 29.5 million adults had psoriasis, corresponding to a physician diagnosed lifetime prevalence of 0.59% (95% uncertainty interval 0.19% to 1.66%) of the adult population worldwide.

![Lifetime (physician or dermatologist diagnosed) prevalence of psoriasis in adults by country. Details about countries with observed or extrapolated data are given in [fig 1](#f1){ref-type="fig"} and supplementary material 2 (eTables 6-11)](parr052230.f5){#f5}

Additional sources of heterogeneity in the estimates were factors such as type of diagnostic method (self-reported, or diagnosis made by a physician or dermatologist) and type of prevalence estimate (period, point, or lifetime prevalence). Specifically, the self-reported lifetime prevalence of psoriasis for the adult population could be almost twice as high (3.77%, 95% uncertainty interval 1.32% to 12.27% in Australasia, and 3.63%, 2.36% to 5.43% in western Europe) and up to 1.12% (0.38% to 2.84%) globally, affecting approximately 55.8 million adults worldwide. Supplementary material 2 (eTables 6-11) shows the prevalence estimates for the 21 regions and 189 countries, and according to the type of diagnoses (physician, dermatologist, or self-report) and lifetime prevalence.

Discussion
==========

Main findings
-------------

This systematic review highlighted that epidemiological data on the incidence of psoriasis are limited, with studies conducted mainly in Europe and North America. Findings revealed consistency across studies about the bimodal age pattern of the onset of the disease. No agreement was found on specific sex differences or trends over time.

The prevalence of the disease was highest in high income countries such as Australasia, western Europe, central Europe, and North America. However, the largest adult populations affected by psoriasis lived in the US, India, and China, followed by Germany, Brazil, France, and the UK. Both the incidence and the prevalence of psoriasis had a strong association with age; the disease was less common in children and occurred more frequently in adults.

Strengths and limitation of the study
-------------------------------------

The study has several key strengths. Firstly, we undertook an extensive systematic review to search for all available literature since inception by using 11 electronic and regional databases with no restriction on language. Secondly, we used a bayesian framework approach to analyse the data, which is the optimal technique when data are sparse and heterogeneous.[@ref14] Thirdly, the statistical model was adjusted for potential sources of heterogeneity, such as age strata, type of diagnostic method, and type of prevalence measure used to calculate the prevalence of the disease. Finally, our analysis generated estimates for 21 regions and 189 countries of the world.

Limitations of the study also need to be acknowledged. Firstly, because of limited information on the incidence of psoriasis, it was not possible to include these data in the statistical model. Secondly, in many low income and middle income countries, only small studies with limited information were available, which resulted in greater uncertainty for some estimates. Thirdly, it was not possible to provide estimates by sex and by five year age bands because of the reporting of the data in the included studies; therefore, no age standardised estimates were calculated. However, by using the information on wide age strata we could estimate the prevalence of psoriasis in children, adults, and the overall population. Fourthly, individual studies provided limited information on their sample sizes; therefore, we could not include this information in the statistical model to give more weight to larger studies. Fifthly, the grouping and hierarchy of the countries within region and super region, which aligns with the Global Burden of Disease methods, are mainly based on geography and income. Therefore, these methods might have influenced the income related patterns highlighted in the findings. Finally, because of the complete lack of information for several countries and regions, in some circumstances we could only use estimates of the wider regions or super regions for countries they were nested in. For this reason, estimates for countries with no data might be helpful in guiding policy makers, healthcare practitioners, and patients, but need to be interpreted with caution. In particular, these estimates might underestimate or overestimate the true values because they have been extrapolated from the regions or super regions the countries are nested in. Nevertheless, given the long term plan of the Global Psoriasis Atlas, future iterations of the model will include new data that will lead to more accurate estimates of the prevalence of psoriasis, particularly in countries with no observed data currently.

Comparison with other studies
-----------------------------

Research performing similar analyses is limited.[@ref11] [@ref12] Hay and colleagues[@ref11] provided estimates of the prevalence of psoriasis for 21 regions of the world. Our estimates are lower than their findings, with the main differences in the data sources used. Our systematic review was more extensive and included more recent studies. Furthermore, our statistical model adjusted for important sources of heterogeneity, such as type of diagnostic methods and type of prevalence measure. If we restricted our analysis to the self-reported lifetime prevalence of psoriasis, our estimate of the global prevalence of psoriasis would be similar.[@ref12] A major strength of our research compared with Hay and colleagues[@ref11] and James and colleagues[@ref12] is that we were able to provide a measure of the prevalence of psoriasis for 189 countries. Importantly, data included in our study cover the most comprehensive existing scientific literature identified from 11 electronic and regional databases compared with two electronic databases searched in the studies by Hay and colleagues[@ref11] and James and colleagues.[@ref12]

In contrast to previous suggestions,[@ref3] [@ref8] we did not find any clear north-south gradient. Conversely, it appeared that the prevalence of psoriasis varied with income, which is similar to the distribution of the disease burden measured as disability adjusted life years (DALYs) by Karimkhani and colleagues.[@ref29] Countries located in high income regions had a higher prevalence of psoriasis compared with low income countries and regions. There are several possible explanations for this observed pattern. Firstly, the results might be because high income countries have better healthcare systems, increased awareness of the disease, better data quality, and studies from these countries report data from large population based and nationally representative databases. Secondly, the structure of the hierarchical model used was mainly based on geography and income, which might have exacerbated the income related patterns of the findings. Thirdly, high income countries have a larger proportion of older people in the population, which means life expectancy is higher and so there is an increased prevalence of psoriasis.[@ref3] Finally, the lack of access to healthcare for many people with psoriasis will contribute to an underestimate of its prevalence in many least developed countries.

Interpretation of the findings
------------------------------

Our study revealed a high country specific variation in the prevalence of psoriasis. Figures were relatively low in regions with young populations, such as south Asia and sub-Saharan Africa, and figures were relatively high in regions with older populations, such as the high income regions. This finding was because of the strong association between the prevalence of psoriasis and age.

Our main analysis reported estimates of the lifetime prevalence of psoriasis according to physician or dermatologist diagnosis. However, these figures might be underestimates of the true prevalence of the disease because most of the data came from studies using databases that only reflect people with psoriasis who sought healthcare; they might not reflect the underdiagnosed population. Conversely, when the analyses reported lifetime prevalence estimates of self-reported psoriasis, the figures were higher in comparison, but there was a risk of misdiagnosis of the disease. This finding is consistent with a recent study from Denmark, which found that the prevalence of self-reported psoriasis was higher than the physician reported prevalence.[@ref30]

Conclusions
-----------

Data on the incidence and prevalence of psoriasis have increased in recent years. However, considerable gaps exist in the geographical areas that report this information, particularly from low and middle income countries.

Psoriasis is recognised as a chronic and disabling non-communicable disease, and people affected have a highly visible condition that can be stigmatising. Accounting for population growth and ageing, and the fact that psoriasis mainly affects the adult population, the burden associated with psoriasis could continue to rise.

A clear need exists to improve the quality and increase the amount of data on the epidemiology of psoriasis. Methods, diagnostic criteria, and reporting of the incidence and prevalence of the disease should be standardised. An improved understanding of the epidemiology of psoriasis is important so that resources can be allocated to reduce morbidity, disability, and mortality associated with the disease.

### What is already known on this topic

1.  Psoriasis is a chronic, disabling skin disease associated with psychological, metabolic, arthritic, and cardiovascular comorbidities

2.  In 2014, the World Health Organization recognised psoriasis as a serious non-communicable disease and its report called for greater understanding of the epidemiology of the disease

3.  The Global Burden of Disease group has produced estimates on the prevalence of psoriasis for 21 regions of the world but not for individual countries

### What this study adds

1.  This systematic review and meta-analysis provides global, regional, and country specific estimates of the prevalence of psoriasis

2.  Psoriasis is a common disease that mainly affects the adult population, and is more frequent in high income countries

3.  An improved understanding of the epidemiology of psoriasis is important when allocating resources to reduce morbidity, disability, and mortality associated with the disease
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